Johan Vingerhoets

3.8k total citations
46 papers, 2.6k citations indexed

About

Johan Vingerhoets is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Johan Vingerhoets has authored 46 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Infectious Diseases, 37 papers in Virology and 9 papers in Epidemiology. Recurrent topics in Johan Vingerhoets's work include HIV Research and Treatment (37 papers), HIV/AIDS drug development and treatment (37 papers) and HIV/AIDS Research and Interventions (26 papers). Johan Vingerhoets is often cited by papers focused on HIV Research and Treatment (37 papers), HIV/AIDS drug development and treatment (37 papers) and HIV/AIDS Research and Interventions (26 papers). Johan Vingerhoets collaborates with scholars based in United States, Belgium and Spain. Johan Vingerhoets's co-authors include Gastón Picchio, Hilde Azijn, Marie‐Pierre de Béthune, Brian Woodfall, Monika Peeters, Goedele De Smedt, L Rimsky, Steven Nijs, Lotke Tambuyzer and Katia Boven and has published in prestigious journals such as The Lancet, Biochemistry and Clinical Infectious Diseases.

In The Last Decade

Johan Vingerhoets

45 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Johan Vingerhoets United States	22	2.4k	2.1k	556	318	176	46	2.6k
George J. Hanna United States	29	2.6k 1.1×	2.4k 1.2×	456 0.8×	231 0.7×	434 2.5×	77	3.1k
Brian Woodfall United States	20	1.8k 0.7×	1.4k 0.7×	363 0.7×	186 0.6×	208 1.2×	29	1.9k
Benoît Trottier Canada	19	1.7k 0.7×	1.5k 0.7×	390 0.7×	252 0.8×	374 2.1×	68	2.2k
Nicolas Margot United States	33	2.7k 1.1×	2.5k 1.2×	488 0.9×	413 1.3×	193 1.1×	73	2.9k
Javier O Morales-Ramirez United States	11	1.8k 0.7×	1.5k 0.7×	231 0.4×	232 0.7×	383 2.2×	13	1.9k
Marshall W. Fordyce United States	16	1.5k 0.6×	955 0.5×	443 0.8×	179 0.6×	500 2.8×	30	1.8k
Annemarie M. J. Wensing Netherlands	13	1.6k 0.6×	1.4k 0.7×	333 0.6×	214 0.7×	87 0.5×	23	1.8k
Andrew Mulato United States	22	1.6k 0.6×	1.2k 0.6×	586 1.1×	315 1.0×	174 1.0×	33	2.1k
Bach-Yen Nguyen United States	12	1.6k 0.7×	1.1k 0.6×	720 1.3×	240 0.8×	316 1.8×	13	2.2k
Susan L. Ford United States	22	1.5k 0.6×	1.1k 0.5×	391 0.7×	166 0.5×	215 1.2×	56	1.8k

Countries citing papers authored by Johan Vingerhoets

Since Specialization

Citations

This map shows the geographic impact of Johan Vingerhoets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Vingerhoets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Vingerhoets more than expected).

Fields of papers citing papers by Johan Vingerhoets

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Vingerhoets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Vingerhoets. The network helps show where Johan Vingerhoets may publish in the future.

Co-authorship network of co-authors of Johan Vingerhoets

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Vingerhoets. A scholar is included among the top collaborators of Johan Vingerhoets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Vingerhoets. Johan Vingerhoets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Xiaodi, Jarek Juraszek, Lucy Rutten, et al.. (2023). Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike. PLoS Pathogens. 19(5). e1011308–e1011308. 5 indexed citations

Lagatie, Ole, Fien Vanroye, Daniel J Stieh, et al.. (2023). Towards Novel HIV-1 Serodiagnostic Tests without Vaccine-Induced Seroreactivity. Microbiology Spectrum. 11(3). e0071523–e0071523. 3 indexed citations

Malcolm, Bruce A., et al.. (2018). PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials. Antiviral Research. 153. 70–77. 5 indexed citations

Geluykens, Peggy, et al.. (2013). A Fluorescence-Based High-Throughput Screening Assay to Identify HIV-1 Inhibitors. Methods in molecular biology. 1030. 3–9. 3 indexed citations

Rimsky, L, Veerle Van Eygen, Annemie Hoogstoel, et al.. (2013). 96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials. Antiviral Therapy. 18(8). 967–977. 35 indexed citations

Vingerhoets, Johan, L Rimsky, Veerle Van Eygen, et al.. (2012). Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response. Antiviral Therapy. 18(2). 253–256. 31 indexed citations

Picchio, Gastón, Johan Vingerhoets, Lotke Tambuyzer, et al.. (2011). Short Communication Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples Received for Routine HIV Type 1 Resistance Testing in the United States. AIDS Research and Human Retroviruses. 27(12). 1271–1275. 16 indexed citations

Tambuyzer, Lotke, et al.. (2011). Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 58(1). 18–22. 60 indexed citations

Rimsky, L, Johan Vingerhoets, Veerle Van Eygen, et al.. (2011). Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 59(1). 39–46. 133 indexed citations

10.

Tambuyzer, Lotke, Johan Vingerhoets, Hilde Azijn, et al.. (2010). Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies. AIDS Research and Human Retroviruses. 26(11). 1197–1205. 45 indexed citations

11.

Vingerhoets, Johan, Hilde Azijn, Lotke Tambuyzer, et al.. (2010). Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data. AIDS Research and Human Retroviruses. 26(6). 621–624. 11 indexed citations

12.

Yéni, Patrick, Anthony Mills, Monika Peeters, et al.. (2010). Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research. 8(7). 564–576. 2 indexed citations

13.

Trottier, Benoît, Giovanni Di Perri, José Valdez Madruga, et al.. (2010). Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2. HIV Clinical Trials. 11(4). 175–185. 9 indexed citations

14.

Kakuda, Thomas N., Janet R. Wade, Eric Snoeck, et al.. (2010). Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. Clinical Pharmacology & Therapeutics. 88(5). 695–703. 37 indexed citations

15.

Nelson, Mark, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.. (2010). A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 25(3). 335–340. 30 indexed citations

16.

Vingerhoets, Johan, Lotke Tambuyzer, Hilde Azijn, et al.. (2010). Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 24(4). 503–514. 137 indexed citations

17.

Peeters, Monika, Johan Vingerhoets, Lotke Tambuyzer, et al.. (2010). Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials. AIDS. 24(6). 921–924. 12 indexed citations

18.

Katlama, Christine, Richard Haubrich, Jacob Lalezari, et al.. (2009). Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 23(17). 2289–2300. 148 indexed citations

19.

Madruga, José Valdez, Pedro Cahn, Beatriz Grinsztejn, et al.. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet. 370(9581). 29–38. 403 indexed citations

20.

Harrigan, P. Richard, Theresa Mo, Brian Wynhoven, et al.. (2005). Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 19(6). 549–554. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact